Pharvaris (PHVS) reports positive Phase 3 data for deucrictibant XR in HAE prevention
Pharvaris said its pivotal CHAPTER-3 Phase 3 study of deucrictibant XR met its primary endpoint with statistically significant and clinically meaningful topline results in preventing hereditary angioedema attacks. The result strengthens the case for Pharvaris’s oral prophylaxis program, but the magnitude and full safety detail remain undisclosed in the announcement excerpt.
The story
Pharvaris announced on Sept. 8 that CHAPTER-3, a pivotal Phase 3 study evaluating an extended-release tablet of deucrictibant for HAE attack prevention, produced statistically significant and clinically meaningful topline results. The company said the study met its primary endpoint.
The study tests the prophylaxis use of deucrictibant XR, an oral bradykinin B2 receptor antagonist. Pharvaris is developing the drug for bradykinin-mediated angioedema, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency; the result therefore addresses the central clinical question for its prevention program rather than an earlier-stage signal.
The direct commercial link is Pharvaris itself: a positive pivotal study could support the company's regulatory and commercialization plans for an oral HAE prophylaxis product. No partner, regulatory filing timeline or comparative data against existing preventive therapies have been identified.
The evidence is positive but incomplete at the topline level. Key details including treatment effect size, attack reduction data, statistical measures and safety profile will determine how much the result changes the product's clinical and competitive positioning.
The next points to watch are Pharvaris's full CHAPTER-3 dataset, including attack reduction, statistical details and adverse events, followed by any regulatory submission or agency interaction.
Our read · Tue, Sep 8
Pharvaris (PHVS) said its CHAPTER-3 Phase 3 study met its primary endpoint in preventing hereditary angioedema attacks.
Why. The result improves the clinical and regulatory setup for PHVS because CHAPTER-3 is a pivotal Phase 3 prophylaxis study and the company describes the topline outcome as statistically significant and clinically meaningful. The read is not strong enough for a dated directional call yet: the announcement excerpt omits the treatment effect, patient count, p-value, safety findings and regulatory timetable.
Both cases
What could change this view: A small or poorly differentiated treatment effect, an unfavorable safety profile, or a delayed regulatory path would weaken the positive read.
Who reported it · 1
Keep reading
Latest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by GlobeNewswire as Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →